BioSight Ltd.
- Country
- 🇮🇱Israel
- Ownership
- Subsidiary
- Established
- 2000-01-01
- Employees
- 11
- Market Cap
- -
Clinical Trials
4
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
A Phase I/II Dose Escalation and Expansion Study of BST-236 Plus Venetoclax in Patients With Unfit Newly Diagnosed AML
- First Posted Date
- 2022-08-16
- Last Posted Date
- 2023-04-04
- Lead Sponsor
- BioSight Ltd.
- Target Recruit Count
- 80
- Registration Number
- NCT05503355
- Locations
- 🇺🇸
Northwestern Memorial Hospital, Chicago, Illinois, United States
🇺🇸The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸University of Virginia Cancer Center, Charlottesville, Virginia, United States
Phase 2, Open-Label, Single Arm Study, With BST-236 in Adults With R/R AML or Higher-Risk MDS
- Conditions
- MDSRelapse/RecurrenceAML, AdultRefractory Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2021-02-11
- Last Posted Date
- 2023-03-09
- Lead Sponsor
- BioSight Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT04749355
- Locations
- 🇺🇸
Ochsner LSU Health Shreveport - Academic Medical Center, Shreveport, Louisiana, United States
🇺🇸The University of Texas MD Anderson Cancer center, Houston, Texas, United States
🇺🇸University of Virginia Cancer Center, Charlottesville, Virginia, United States
Efficacy and Safety of BST-236 in Newly Diagnosed Acute Myeloid Leukemia Patients, Unfit for Standard Induction Therapy
- First Posted Date
- 2018-02-19
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- BioSight Ltd.
- Target Recruit Count
- 66
- Registration Number
- NCT03435848
- Locations
- 🇺🇸
Augusta University Georgia Cancer Center, Augusta, Georgia, United States
🇺🇸Northwestern Memorial Hospital, Chicago, Illinois, United States
🇺🇸Franciscan Physician Network Oncology and Hematology Specialists, Indianapolis, Indiana, United States
Study Evaluating the Safety and Efficacy of Astarabine in Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
- Conditions
- Acute Myeloid LeukemiaAcute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2015-09-09
- Last Posted Date
- 2017-09-27
- Lead Sponsor
- BioSight Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT02544438
- Locations
- 🇮🇱
Rambam medical center hematology department, Haifa, Israel
🇮🇱Tel Aviv Sourasky Medical Center, Tel Aviv, Israel